Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Breast J ; 18(3): 233-41, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22487060

RESUMEN

Prognosis in patients with carcinomatous meningitis (CM) is poor, and numerous prognostic factors for response and survival have been described, but remain controversial. In general, series are small and involve a heterogeneous type of solid neoplasms. The purpose of this study was to describe a series of patients with breast cancer-associated CM to determine the clinical features and prognostic factors associated with survival. We conducted a retrospective study on 49 patients diagnosed between January 2003 and December 2007 at the Instituto Nacional de Cancerología in Mexico City. CSF cytopathology samples were re-reviewed to confirm the diagnosis. Overall survival (OS) for patients with breast cancer with CM was 7 weeks. Factors independently associated with better OS included absence of encephalopathy at diagnosis (11 weeks versus 1 week; p = .036), low CSF protein content (15 versus 5 weeks; p = .022), and nontriple-negative receptor status in the primary breast cancer tumor (13 versus 3 weeks; p = .015). According to multivariate analysis, patients were divided into favorable and poor prognostic groups, with OS of 14 weeks and 2 weeks, respectively (p < .001). These factors can identify a subgroup of patients who are candidates for an intensive management approach.


Asunto(s)
Neoplasias de la Mama/patología , Carcinomatosis Meníngea/etiología , Carcinomatosis Meníngea/mortalidad , Carcinomatosis Meníngea/secundario , Adulto , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/mortalidad , Líquido Cefalorraquídeo , Femenino , Humanos , Imagen por Resonancia Magnética , Carcinomatosis Meníngea/diagnóstico , Carcinomatosis Meníngea/terapia , Metotrexato/uso terapéutico , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Punción Espinal , Tasa de Supervivencia , Trastuzumab
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA